Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HPV Vaccines Immunogenicity and Safety”

147 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 147 results

Large-scale testing (Phase 3)Study completedNCT00652938
What this trial is testing

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 744
Large-scale testing (Phase 3)WithdrawnNCT02100618
What this trial is testing

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline
Post-approval studies (Phase 4)Looking for participantsNCT07668271
What this trial is testing

Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)

Who this might be right for
Infection by Human Papilloma Virus
Xiamen Innovax Biotech Co., Ltd 720
Large-scale testing (Phase 3)Study completedNCT01462357
What this trial is testing

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 1,079
Testing effectiveness (Phase 2)Study completedNCT00263744
What this trial is testing

Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive

Who this might be right for
Healthy
MedImmune LLC 60
Early research (Phase 1)UnknownNCT04921111
What this trial is testing

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Who this might be right for
HPV Infection Vaccine Safety SCT1000
Sinocelltech Ltd. 240
Large-scale testing (Phase 3)Study completedNCT00290277
What this trial is testing

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 300
Testing effectiveness (Phase 2)Study completedNCT00693615
What this trial is testing

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 60
Testing effectiveness (Phase 2)Looking for participantsNCT07377656
What this trial is testing

Strengthening HPV Immunization Through EPI Leveraged Delivery

Who this might be right for
HPV Vaccine
International Vaccine Institute 115
Large-scale testing (Phase 3)Active Not RecruitingNCT04537156
What this trial is testing

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Who this might be right for
Cervical Intraepithelial NeoplasiaCervical CancerCondylomata Acuminata
Xiamen University 9,327
Testing effectiveness (Phase 2)Study completedNCT00309166
What this trial is testing

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 270
Large-scale testing (Phase 3)Study completedNCT00552279
What this trial is testing

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 805
Testing effectiveness (Phase 2)Looking for participantsNCT06319963
What this trial is testing

Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Who this might be right for
HPV-Related Cervical CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
Theravectys S.A. 72
Large-scale testing (Phase 3)Study completedNCT02993757
What this trial is testing

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Who this might be right for
Dengue FeverDengue Hemorrhagic FeverHuman Papillomavirus Disease
Sanofi Pasteur, a Sanofi Company 528
Large-scale testing (Phase 3)Study completedNCT04313244
What this trial is testing

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Who this might be right for
Dengue Fever
Takeda 614
Large-scale testing (Phase 3)Study completedNCT00196924
What this trial is testing

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 2,067
Large-scale testing (Phase 3)Study completedNCT00637195
What this trial is testing

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Who this might be right for
Infections, PapillomavirusPapillomavirus Vaccines
GlaxoSmithKline 152
Large-scale testing (Phase 3)Study completedNCT03493542
What this trial is testing

Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Who this might be right for
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Merck Sharp & Dohme LLC 766
Testing effectiveness (Phase 2)Study completedNCT00586339
What this trial is testing

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 150
Testing effectiveness (Phase 2)Study completedNCT02529930
What this trial is testing

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Who this might be right for
High Grade Cervical Intraepithelial Neoplasia
Nykode Therapeutics ASA 34
Next Page